INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER

顺铂/卡铂和 FUDR 腹膜内治疗卵巢癌

• 批准号: 6277031
• 负责人: FRANCO MUGGIA
• 金额: $ 2.03万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6277031
• 关键词: carboplatin; cis platinum compound; clinical research; combination chemotherapy; female; floxuridine; human subject; human therapy evaluation; injection /infusion; neoplasm /cancer chemotherapy; ovary neoplasms; peritoneal cavity

Standard treatment of stage-III and -IV ovarian cancer has been surgical resection followed by intravenous paclitaxel and a platinum compound, which stops progression in 80% and results in negative findings in 20% of patients at Rsecond-lookS surgery. When residual disease is detected, therapy is less clear. In pilot studies, intraperitoneal (IP) floxuridine (FUdR) and cisplatin showed encouraging results. Subjects to be entered will be those who have completed stage-I chemotherapy for ovarian cancer but at Rsecond-lookS surgery have 2 1 cm peritoneal disease. IP catheters will be placed. FUdR (3g) will be given IP for 3 days, and cisplatin (60 mg/m2) will be given IP on the third day. (When applicable, carboplatin [500 ml] may follow immediately after FUdR.) This treatment cycle will be repeated every 3 weeks. Total duration of treatment will consist of 6 consecutive cycles as long as there is no progression or intolerable toxicity. Subjects will be assessed with a CT scan of the abdomen with IP contrast 6 weeks and one year after therapy or whenever recurrence is suspected.

III期和IV期卵巢癌的标准治疗是手术 切除后静脉注射紫杉醇和铂化合物， 80%的患者停止进展，20%的患者出现阴性结果 进行第二次手术的病人。 当残留疾病 检测，治疗是不太清楚。 在初步研究中，腹膜内（IP） 尿嘧啶核苷（FUdR）和顺铂显示了令人鼓舞的结果。 科目 进入将是那些谁完成了第一阶段化疗， 卵巢癌，但在第二次看手术有21厘米的腹膜 疾病将置入IP导管。 FUdR（3g）将IP给药， 第3天给予顺铂（60 mg/m2）IP。 (When适用，卡铂[500 ml]可在 FUdR。）该治疗周期将每3周重复一次。 总 治疗持续时间将包括6个连续周期，只要 没有进展或不可耐受的毒性。 受试者将 使用IP造影剂进行腹部CT扫描评估6周， 治疗后1年或怀疑复发时。